Comment on

• Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.

  DeFilipp Z, Kim HT, Knight LW, O'Connor SM, Dhaver SE, White M, Dholaria B, Schroeder MA, Vasu S, Abedin S, Chung J, El-Jawahri A, Frigault MJ, McAfee S, Newcomb RA, O'Donnell PV, Spitzer TR, Chen YB, Hobbs GS. DeFilipp Z, et al. Blood. 2025 May 15;145(20):2312-2316. doi: 10.1182/blood.2024028005. Blood. 2025. PMID: 40106768 Clinical Trial.